Cargando…

E-Cigarettes—a review of the evidence—harm versus harm reduction

The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape...

Descripción completa

Detalles Bibliográficos
Autores principales: Feeney, Susan, Rossetti, Victoria, Terrien, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968985/
https://www.ncbi.nlm.nih.gov/pubmed/35370428
http://dx.doi.org/10.1177/1179173X221087524
_version_ 1784679162299023360
author Feeney, Susan
Rossetti, Victoria
Terrien, Jill
author_facet Feeney, Susan
Rossetti, Victoria
Terrien, Jill
author_sort Feeney, Susan
collection PubMed
description The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape pens, mods, and vaping. The growing use of ENDS, or e-cigarettes, in the US and globally across populations is dramatic. Although users may think that e-cigarettes are less harmful than combustible tobacco products, the evidence shows that there are known risks and harms for users. E-cigarettes have varying amounts of toxicants, nicotine, and carcinogens and put the user at risk for lung diseases and COVID-19 similar to smokers. Currently, most governing bodies have not approved e-cigarettes as a smoking cessation tool but do state if a person has failed conventional smoking cessation treatments that e-cigarettes used alone for the short term may help those to quit combustible tobacco and nicotine. A shared decision-making approach should be used when discussing e-cigarettes as a harm reduction tool. More studies and long-term data are needed to assess potential benefits and harms. What is known is that prevention efforts and policy are needed to avoid adolescents and other vulnerable populations from initiating tobacco or e-cigarette use.
format Online
Article
Text
id pubmed-8968985
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89689852022-04-01 E-Cigarettes—a review of the evidence—harm versus harm reduction Feeney, Susan Rossetti, Victoria Terrien, Jill Tob Use Insights Review The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape pens, mods, and vaping. The growing use of ENDS, or e-cigarettes, in the US and globally across populations is dramatic. Although users may think that e-cigarettes are less harmful than combustible tobacco products, the evidence shows that there are known risks and harms for users. E-cigarettes have varying amounts of toxicants, nicotine, and carcinogens and put the user at risk for lung diseases and COVID-19 similar to smokers. Currently, most governing bodies have not approved e-cigarettes as a smoking cessation tool but do state if a person has failed conventional smoking cessation treatments that e-cigarettes used alone for the short term may help those to quit combustible tobacco and nicotine. A shared decision-making approach should be used when discussing e-cigarettes as a harm reduction tool. More studies and long-term data are needed to assess potential benefits and harms. What is known is that prevention efforts and policy are needed to avoid adolescents and other vulnerable populations from initiating tobacco or e-cigarette use. SAGE Publications 2022-03-29 /pmc/articles/PMC8968985/ /pubmed/35370428 http://dx.doi.org/10.1177/1179173X221087524 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Feeney, Susan
Rossetti, Victoria
Terrien, Jill
E-Cigarettes—a review of the evidence—harm versus harm reduction
title E-Cigarettes—a review of the evidence—harm versus harm reduction
title_full E-Cigarettes—a review of the evidence—harm versus harm reduction
title_fullStr E-Cigarettes—a review of the evidence—harm versus harm reduction
title_full_unstemmed E-Cigarettes—a review of the evidence—harm versus harm reduction
title_short E-Cigarettes—a review of the evidence—harm versus harm reduction
title_sort e-cigarettes—a review of the evidence—harm versus harm reduction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968985/
https://www.ncbi.nlm.nih.gov/pubmed/35370428
http://dx.doi.org/10.1177/1179173X221087524
work_keys_str_mv AT feeneysusan ecigarettesareviewoftheevidenceharmversusharmreduction
AT rossettivictoria ecigarettesareviewoftheevidenceharmversusharmreduction
AT terrienjill ecigarettesareviewoftheevidenceharmversusharmreduction